1.Arias CA, Murray BE: The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012, 10(4):266–278.
2.Hollenbeck BL, Rice LB: Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012, 3(5):421–433.
3.Murray BE: Vancomycin-resistant enterococcal infections. N Engl J Med 2000, 342(10):710–721.
4.Chacko KI, Sullivan MJ, Beckford C, Altman DR, Ciferri B, Pak TR, Sebra R, Kasarskis A, Hamula CL, van Bakel H: Genetic Basis of Emerging Vancomycin, Linezolid, and Daptomycin Heteroresistance in a Case of Persistent Enterococcus faecium Bacteremia. Antimicrob Agents Chemother 2018, 62(4).
5.Deshpande LM, Castanheira M, Flamm RK, Mendes RE: Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. J Antimicrob Chemother 2018, 73(9):2314–2322.
6.Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP: Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002, 50(5):743–746.
7.Ruggero KA, Schroeder LK, Schreckenberger PC, Mankin AS, Quinn JP: Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003, 47(3):511–513.
8.Burleson BS, Ritchie DJ, Micek ST, Dunne WM: Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy 2004, 24(9):1225–1231.
9.Diaz L, Kiratisin P, Mendes RE, Panesso D, Singh KV, Arias CA: Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012, 56(7):3917–3922.
10.Baccani I, Antonelli A, Galano A, Bartalesi F, Bartoloni A, Rossolini GM: Linezolid-Resistant Enterococcus faecalis Infection Following Prolonged Low-Dosage Linezolid Treatment for Multidrug-Resistant Tuberculosis. Clin Infect Dis 2017, 65(12):2159–2160.
11.Sanchez-Gomez JC, Fraile-Malmierca F, Valverde-Romero ED, Sanchez M, Garcia-Rodriguez JA, Garcia-Sanchez JE: Linezolid-resistant Enterococcus faecalis: first report in Spain. J Chemother 2006, 18(4):440–442.
12.Lopez-Salas P, Llaca-Diaz J, Morfin-Otero R, Tinoco JC, Rodriguez-Noriega E, Salcido-Gutierres L, Gonzalez GM, Mendoza-Olazaran S, Garza-Gonzalez E: Virulence and antibiotic resistance of Enterococcus faecalis clinical isolates recovered from three states of Mexico. Detection of linezolid resistance. Arch Med Res 2013, 44(6):422–428.
13.de Almeida LM, de Araujo MR, Iwasaki MF, Sacramento AG, Rocha D, da Silva LP, Pavez M, de Brito AC, Ito LC, Gales AC et al: Linezolid resistance in vancomycin-resistant Enterococcus faecalis and Enterococcus faecium isolates in a Brazilian hospital. Antimicrob Agents Chemother 2014, 58(5):2993–2994.
14.Chen M, Pan H, Lou Y, Wu Z, Zhang J, Huang Y, Yu W, Qiu Y: Epidemiological characteristics and genetic structure of linezolid-resistant Enterococcus faecalis. Infect Drug Resist 2018, 11:2397–2409.
15.Gomez-Gil R, Romero-Gomez MP, Garcia-Arias A, Ubeda MG, Busselo MS, Cisterna R, Gutierrez-Altes A, Mingorance J: Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. Diagn Microbiol Infect Dis 2009, 65(2):175–179.
16.Wang L, He Y, Xia Y, Wang H, Liang S: Investigation of mechanism and molecular epidemiology of linezolid-resistant Enterococcus faecalis in China. Infect Genet Evol 2014, 26:14–19.
17.Ntokou E, Stathopoulos C, Kristo I, Dimitroulia E, Labrou M, Vasdeki A, Makris D, Zakynthinos E, Tsakris A, Pournaras S: Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2012, 67(8):1819–1823.
18.Bai B, Hu K, Zeng J, Yao W, Li D, Pu Z, Chen Z, Cheng H, Zheng J, Pan W et al: Linezolid Consumption Facilitates the Development of Linezolid Resistance in Enterococcus faecalis in a Tertiary-Care Hospital: A 5-Year Surveillance Study. Microb Drug Resist 2019, 25(6):791–798.
19.Harris AD, Karchmer TB, Carmeli Y, Samore MH: Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001, 32(7):1055–1061.
20.Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y: Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002, 34(12):1558–1563.
21.Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infection. Am J Med 1991, 91(3B):72S–75S.
22.Emori TG, Gaynes RP: An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993, 6(4):428–442.
23.Diekema DJ, BootsMiller BJ, Vaughn TE, Woolson RF, Yankey JW, Ernst EJ, Flach SD, Ward MM, Franciscus CL, Pfaller MA et al: Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004, 38(1):78–85.
24.Schwarz S, Werckenthin C, Kehrenberg C: Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob Agents Chemother 2000, 44(9):2530–2533.
25.Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357(9263):1179.
26.Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002, 346(11):867–869.
27.Dobbs TE, Patel M, Waites KB, Moser SA, Stamm AM, Hoesley CJ: Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006, 44(9):3368–3370.
28.Cafini F, Nguyen le TT, Higashide M, Roman F, Prieto J, Morikawa K: Horizontal gene transmission of the cfr gene to MRSA and Enterococcus: role of Staphylococcus epidermidis as a reservoir and alternative pathway for the spread of linezolid resistance. J Antimicrob Chemother 2016, 71(3):587–592.
29.Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP: Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002, 35(10):1269–1272.
30.Smith TT, Tamma PD, Do TB, Dzintars KE, Zhao Y, Cosgrove SE, Avdic E: Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium. Diagn Microbiol Infect Dis 2018, 91(2):161–163.
31.Greene MH, Harris BD, Nesbitt WJ, Watson ML, Wright PW, Talbot TR, Nelson GE: Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus. Open Forum Infect Dis 2018, 5(10):ofy185.
32.Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C: Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008, 52(6):2256–2259.
33.Souli M, Sakka V, Galani I, Antoniadou A, Galani L, Siafakas N, Zerva L, Fytrou H, Tsiodras S, Giamarellou H: Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis. Int J Antimicrob Agents 2009, 33(2):137–142.
34.Cho SY, Kim HM, Chung DR, Kim SH, Huh HJ, Kang CI, Peck KR, Lee NY, Song JH: Resistance mechanisms and clinical characteristics of linezolid-resistant Enterococcus faecium isolates: A single-centre study in South Korea. J Glob Antimicrob Resist 2018, 12:44–47.
35.Mendes RE, Deshpande L, Rodriguez-Noriega E, Ross JE, Jones RN, Morfin-Otero R: First report of Staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization. J Clin Microbiol 2010, 48(8):3041–3043.
36.Bi R, Qin T, Fan W, Ma P, Gu B: The emerging problem of linezolid-resistant enterococci. J Glob Antimicrob Resist 2018, 13:11–19.
37.Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ: Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. Clin Infect Dis 2016, 62(10):1242–1250.
38.Garcia-Martinez L, Gracia-Ahulfinger I, Machuca I, Cantisan S, De La Fuente S, Natera C, Perez-Nadales E, Vidal E, Rivero A, Rodriguez-Lopez F et al: Impact of the PROVAUR stewardship programme on linezolid resistance in a tertiary university hospital: a before-and-after interventional study. J Antimicrob Chemother 2016, 71(9):2606–2611.